Using Hsp70 combined with tumor lysate to promote the efficiency of tumor vaccine

• Main Authors: Zhi- Shen Lai, 賴峙伸
• Other Authors: Shye-Jye Tang
• Format: Others
• Language: zh-TW
• Published: 2005
• Online Access: http://ndltd.ncl.edu.tw/handle/00133162588048767796

碩士 === 國立臺灣海洋大學 === 生物科技研究所 === 93 === Lung cancer cell derived Heat shock proteins bind with tumor antigens elicted MHC class I restricted antigen-specific CD8+ cytotoxic T-lymphocyte (CTL) response and MHC class II restricted antigen-specific CD4+ response. These responses reject tumor cell growth in the animal model. In recent years, take egg albumen (ovalbumin) as the strong antigen displayed anti-tumor cell growth was established in the EL4 cell. The model system often used to know the possibility mechanism suppress tumor growth and develops the anti-cancer medicine in the animal. In the recent experiment, express OVA peptide on the APC cell surface by the Hsp70 enhanced immune response and reject tumor cell growth. The intention of our experiment is wish to product great quantity recombinant Hsp70 in E.coli, complex with tumor lysate derived tumor antigens in vitro and elited anti-tumor activity in vivo. Make cell lysate from LLC-1, mixed with trypsin to get peptides below 10 kDa by gel electrophoresis extraction. After recombinant Hsp70 added, subcutaneous injection into mouse twice between one weeks. One week after last injection, the CTL has response to LLC-1 but not B16. It indicated that immune response stimulated by HSP70-peptide complex is specific to tumor cell. Furthermore, the immune response rejected tumor cell growth in vivo. Without expect, the HSP70-peptide complex system can not used in OVA system. Further research is required to find out detail mechanism in OVA system.